| __timestamp | Agios Pharmaceuticals, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 17986000 |
| Thursday, January 1, 2015 | 35992000 | 32480000 |
| Friday, January 1, 2016 | 50714000 | 68081000 |
| Sunday, January 1, 2017 | 71124000 | 169906000 |
| Monday, January 1, 2018 | 114145000 | 248932000 |
| Tuesday, January 1, 2019 | 132034000 | 354100000 |
| Wednesday, January 1, 2020 | 149070000 | 433300000 |
| Friday, January 1, 2021 | 121445000 | 583300000 |
| Saturday, January 1, 2022 | 121673000 | 752700000 |
| Sunday, January 1, 2023 | 119903000 | 887600000 |
| Monday, January 1, 2024 | 156784000 | 1007200000 |
Cracking the code
In the competitive world of biotechnology, managing expenses is crucial for sustained growth. This analysis of SG&A (Selling, General, and Administrative) expenses from 2014 to 2023 reveals intriguing trends for Neurocrine Biosciences, Inc. and Agios Pharmaceuticals, Inc. Over this period, Neurocrine Biosciences has seen a staggering increase in SG&A expenses, growing nearly 50 times from 2014 to 2023. In contrast, Agios Pharmaceuticals experienced a more modest growth, with expenses increasing by approximately 6 times.
Neurocrine's aggressive expansion strategy is evident, with its SG&A expenses peaking at nearly $888 million in 2023, reflecting its commitment to scaling operations and market presence. Meanwhile, Agios Pharmaceuticals maintained a steadier pace, with expenses reaching around $120 million in the same year. This divergence highlights differing strategic priorities, with Neurocrine focusing on rapid growth and Agios on sustainable development.
Who Optimizes SG&A Costs Better? Sanofi or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Novavax, Inc.
Selling, General, and Administrative Costs: Alpine Immune Sciences, Inc. vs Agios Pharmaceuticals, Inc.
Comparing SG&A Expenses: Bausch Health Companies Inc. vs Agios Pharmaceuticals, Inc. Trends and Insights
Selling, General, and Administrative Costs: Arrowhead Pharmaceuticals, Inc. vs Agios Pharmaceuticals, Inc.